Medtronic's Renal Denervation Breakthrough: A De-Risked Catalyst Poised for Growth

Related Articles

Is Medtronic Finally Poised for a Turnaround

4 months ago

Is Ionis Pharmaceuticals Poised for a Breakthrough with Tryngolza

4 months ago

Is EcoSolutions Waste Poised for a Biofuel Breakthrough

4 months ago

Is the Stablecoin Market Poised for Explosive Growth

3 months ago

Category

You may also like

Stock News•2 days ago

Fresenius Medical Care: More Favorable Patient Outcomes Will Drive Growth

Fresenius Medical Care's growth potential is tied to new product rollouts and improved patient outcomes. Care Delivery earnings could rise further if outcomes improve, but €80M/quarter CMS incentives ...

FMS

Share

Stock News•1 week ago

Nuwellis Awarded U.S. Patent for Novel Catheter Technology Designed to Enhance Extracorporeal Therapies

Nuwellis received a U.S. patent for a catheter technology that allows customizable length while maintaining structural integrity during ultrafiltration, dialysis, and continuous renal replacement ther...

NUWE

Share

Stock News•1 months ago

Medtronic Bets on Ablation, Robotics, and Hypertension

Medtronic is betting on ablation, robotics, and hypertension therapies as next growth drivers, though tariffs, FX, and pricing pressures cloud near-term upside.

MDT

Share

Stock News•2 months ago

Boston Scientific Advances Coronary Calcium Treatment With Positive Trial Results

Boston Scientific (BSX) met primary safety and effectiveness goals in its pivotal trial for the SEISMIQ 4CE coronary intravascular lithotripsy catheter. The device targets patients with severely calci...

BSX

Share